This study is for adults with a heart condition called ATTR-CM, which stands for transthyretin amyloid cardiomyopathy. In this condition, abnormal proteins build up in the heart, affecting its function. The study aims to see if a new drug, ALXN2220, helps more than a placebo, which is a harmless pill without real medicine.
To join, you must have a confirmed diagnosis of ATTR-CM and meet other health criteria like certain heart measurements and being treated with specific medications. You should not have other types of amyloidosis or recent major heart problems.
- This study will assess your heart health and requires regular visits for check-ups.
- Participants must use contraception if they are of childbearing age.
- Your doctor should think you have at least 6 months to live.
The study will compare the number of heart-related health events between those taking ALXN2220 and those taking the placebo. If you meet the criteria, this could be an opportunity to try a potential new treatment for ATTR-CM with your doctor's guidance.